Neuropathic pain research targets Nav1.7 sodium channels

Researchers are exploring new methods to treat neuropathic pain, which is caused by nerve damage from conditions such as diabetes, herniated discs, or infections like herpes zoster. A preclinical study has focused on the Nav1.7 sodium channel, a key player in pain transmission. While traditional drugs often struggle to target this channel without affecting the heart or brain, scientists have developed humanized monoclonal antibodies designed to bind specifically to Nav1.7.

In laboratory tests involving rats with sciatic nerve injuries, these antibodies successfully reduced sensitivity to pressure without affecting similar channels. The effect lasted at least four days following intravenous administration.

Complementary research into the brain's sensory homunculus explains why certain minor injuries, such as stubbing a toe, cause intense pain. This is due to the high density of nociceptors in extremities and the disproportionately large area the feet and hands occupy within the somatosensory cortex.